Q2 Earnings Estimate for Celcuity Issued By Leerink Partnrs

Celcuity Inc. (NASDAQ:CELC) – Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Celcuity in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.85) for the quarter. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share.

CELC has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a research note on Friday, November 15th. Needham & Company LLC increased their target price on Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Celcuity currently has an average rating of “Buy” and a consensus price target of $30.17.

Celcuity Trading Down 2.7 %

NASDAQ:CELC opened at $12.25 on Friday. The business has a fifty day moving average price of $12.31 and a 200-day moving average price of $14.45. The firm has a market capitalization of $454.84 million, a price-to-earnings ratio of -4.69 and a beta of 0.73. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. Celcuity has a one year low of $10.35 and a one year high of $22.19.

Institutional Trading of Celcuity

Several hedge funds have recently modified their holdings of the company. nVerses Capital LLC purchased a new position in Celcuity during the third quarter valued at $33,000. Prospera Private Wealth LLC acquired a new stake in Celcuity in the third quarter valued at approximately $35,000. Values First Advisors Inc. acquired a new position in shares of Celcuity during the third quarter worth $86,000. SG Americas Securities LLC purchased a new position in shares of Celcuity in the 3rd quarter valued at about $119,000. Finally, Bleakley Financial Group LLC acquired a new stake in Celcuity during the fourth quarter worth approximately $146,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.